CL2018003530A1 - Usos terapéuticos de un inhibidor de c–raf - Google Patents
Usos terapéuticos de un inhibidor de c–rafInfo
- Publication number
- CL2018003530A1 CL2018003530A1 CL2018003530A CL2018003530A CL2018003530A1 CL 2018003530 A1 CL2018003530 A1 CL 2018003530A1 CL 2018003530 A CL2018003530 A CL 2018003530A CL 2018003530 A CL2018003530 A CL 2018003530A CL 2018003530 A1 CL2018003530 A1 CL 2018003530A1
- Authority
- CL
- Chile
- Prior art keywords
- raf inhibitor
- refers
- present
- combination
- protein
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 102000001788 Proto-Oncogene Proteins c-raf Human genes 0.000 title 1
- 108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 102000043136 MAP kinase family Human genes 0.000 abstract 1
- 108091054455 MAP kinase family Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 abstract 1
- 230000004075 alteration Effects 0.000 abstract 1
- 239000003226 mitogen Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE AL USO DE UN INHIBIDOR DE C–RAF PARA EL USO EN EL TRATAMIENTO DE UNA ENFERMEDAD PROLIFERATIVA, EN PARTICULAR, UN TUMOR SÓLIDO QUE ALBERGA PROTEÍNA QUINASA ACTIVADA POR MITÓGENO (MAPK). LA PRESENTE INVENCIÓN TAMBIÉN SE REFIERE A UNA COMBINACIÓN FARMACÉUTICA QUE COMPRENDE (A) POR LO MENOS UNA MOLÉCULA DE ANTICUERPO (POR EJEMPLO, MOLÉCULAS DE ANTICUERPO HUMANIZADAS) QUE SE UNE A LA PROTEÍNA DE MUERTE PROGRAMADA 1 (PD–1), Y (B) UN INHIBIDOR DE C–RAF O SU SAL FARMACÉUTICAMENTE ACEPTABLE. LA PRESENTE INVENCIÓN TAMBIÉN SE REFIERE A UNA COMBINACIÓN DE ESTE TIPO PARA LA ADMINISTRACIÓN SIMULTÁNEA, SEPARADA O SECUENCIAL PARA EL TRATAMIENTO DE UNA ENFERMEDAD PROLIFERATIVA, EN PARTICULAR, UN TUMOR SÓLIDO QUE ALBERGA LA ALTERACIÓN DE LA PROTEÍNA QUINASA ACTIVADA POR MITÓGENO (MAPK), Y A UN ENVASE COMERCIAL QUE COMPRENDE DICHA COMBINACIÓN.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662348720P | 2016-06-10 | 2016-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018003530A1 true CL2018003530A1 (es) | 2019-02-15 |
Family
ID=59215827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018003530A CL2018003530A1 (es) | 2016-06-10 | 2018-12-07 | Usos terapéuticos de un inhibidor de c–raf |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190175609A1 (es) |
| EP (1) | EP3468595A1 (es) |
| JP (1) | JP2019517549A (es) |
| KR (1) | KR20190017767A (es) |
| CN (1) | CN109310761A (es) |
| AU (1) | AU2017279046B2 (es) |
| BR (1) | BR112018075371A2 (es) |
| CA (1) | CA3026876A1 (es) |
| CL (1) | CL2018003530A1 (es) |
| IL (1) | IL262961A (es) |
| MX (1) | MX2018015353A (es) |
| RU (1) | RU2018146886A (es) |
| WO (1) | WO2017212442A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3037456A1 (en) * | 2016-09-19 | 2018-03-22 | Novartis Ag | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor |
| IL270224B1 (en) | 2017-05-02 | 2024-04-01 | Novartis Ag | Combination therapy employing trametinib and a defined raf inhibitor |
| CN113613612B (zh) | 2019-03-08 | 2022-08-02 | 奥瑞斯健康公司 | 用于医疗系统和应用的倾斜机构 |
| EP4563150A3 (en) | 2019-05-13 | 2025-07-23 | Novartis AG | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer |
| US11098031B1 (en) | 2019-10-24 | 2021-08-24 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
| US20230046018A1 (en) * | 2019-12-06 | 2023-02-16 | Medshine Discovery Inc. | Biaryl compound as pan-raf kinase inhibitor |
| CN113912591B (zh) * | 2020-07-08 | 2023-10-20 | 齐鲁制药有限公司 | 联芳基化合物 |
| CN117425650A (zh) * | 2021-06-04 | 2024-01-19 | 齐鲁制药有限公司 | 一种raf激酶抑制剂的晶型及其制备方法 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR090151A1 (es) * | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| AU2015214390B2 (en) * | 2014-02-04 | 2020-05-07 | Merck Sharp & Dohme LLC. | Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer |
| AR101210A1 (es) * | 2014-07-15 | 2016-11-30 | Genentech Inc | Métodos de tratamiento de cáncer usando antagonistas de unión al eje pd-1 e inhibidores de mek |
-
2017
- 2017-06-08 KR KR1020187035219A patent/KR20190017767A/ko not_active Ceased
- 2017-06-08 RU RU2018146886A patent/RU2018146886A/ru not_active Application Discontinuation
- 2017-06-08 AU AU2017279046A patent/AU2017279046B2/en not_active Ceased
- 2017-06-08 CA CA3026876A patent/CA3026876A1/en not_active Abandoned
- 2017-06-08 JP JP2018564296A patent/JP2019517549A/ja active Pending
- 2017-06-08 EP EP17733028.9A patent/EP3468595A1/en not_active Withdrawn
- 2017-06-08 CN CN201780035192.1A patent/CN109310761A/zh active Pending
- 2017-06-08 BR BR112018075371-8A patent/BR112018075371A2/pt not_active Application Discontinuation
- 2017-06-08 MX MX2018015353A patent/MX2018015353A/es unknown
- 2017-06-08 US US16/307,920 patent/US20190175609A1/en not_active Abandoned
- 2017-06-08 WO PCT/IB2017/053405 patent/WO2017212442A1/en not_active Ceased
-
2018
- 2018-11-12 IL IL262961A patent/IL262961A/en unknown
- 2018-12-07 CL CL2018003530A patent/CL2018003530A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3026876A1 (en) | 2017-12-14 |
| BR112018075371A2 (pt) | 2019-03-19 |
| RU2018146886A3 (es) | 2020-10-15 |
| EP3468595A1 (en) | 2019-04-17 |
| AU2017279046B2 (en) | 2020-07-02 |
| RU2018146886A (ru) | 2020-07-10 |
| US20190175609A1 (en) | 2019-06-13 |
| AU2017279046A1 (en) | 2018-12-06 |
| JP2019517549A (ja) | 2019-06-24 |
| MX2018015353A (es) | 2019-09-09 |
| KR20190017767A (ko) | 2019-02-20 |
| WO2017212442A1 (en) | 2017-12-14 |
| IL262961A (en) | 2018-12-31 |
| CN109310761A (zh) | 2019-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018003530A1 (es) | Usos terapéuticos de un inhibidor de c–raf | |
| CL2019000681A1 (es) | Combinaciones terapéuticas que comprenden un inhibidor de raf y un inhibidor de erk. | |
| AR107290A1 (es) | ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
| PH12019500270A1 (en) | Combination therapy for cancer | |
| DOP2018000126A (es) | Proteínas de unión a PD1 y/o LAG3 | |
| ECSP18045497A (es) | Enlazadores de ctla4 | |
| MX2019006954A (es) | Terapia de combinacion de anticuerpos biespecificos anti-cd20/anti-cd3 y agonistas de 4-1bb (cd137). | |
| CL2019003091A1 (es) | Terapia de combinación. | |
| MX377844B (es) | Anticuerpos anti proteína relacionada con el receptor del factor de necrosis tumoral inducida por glucocorticóides (gitr) y sus métodos de uso. | |
| MX385320B (es) | Moléculas de unión específicas para grupo de diferenciación 73 (cd73) y usos de las mismas. | |
| UY35964A (es) | Anticuerpos humanos para pd?1 | |
| CO2019001367A2 (es) | Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123 | |
| MY195474A (en) | Single Domain Antibody and Derivative Proteins Thereof Against Programmed Death Ligand (Pdl1) | |
| AR104812A1 (es) | Combinaciones terapéuticas y métodos para tratar neoplasias | |
| BR112016009797A2 (pt) | anticorpos específicos de ligante 1a do tipo fator de necrose tumoral e composições e usos dos mesmos | |
| MX2018013952A (es) | Marcadores selectivamente desregulados en celulas t reguladoras, infiltrantes de tumores. | |
| BR112017021245A2 (pt) | Anticorpo anti-c-met e conjugado anticorpo anti- c-met-fármaco citotóxico e uso farmacêutico do mesmo | |
| UY36536A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
| AR108317A1 (es) | Composiciones que comprenden coformulación de anticuerpos anti-pd-l1 y anti-ctla-4 | |
| CO2017009433A2 (es) | Proteínas específicas para pioverdina y pioquelina | |
| BR112019007576A2 (pt) | compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais | |
| HK1254635A1 (zh) | C-met抑制剂与pd-1抗体分子的组合及其用途 | |
| BR112017012337A2 (pt) | Método para tratamento de doença falciforme, agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró- fármaco do mesmo, uso de um agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró-fármaco do mesmo, formulação farmacêutica, e, produto de combinação. | |
| CL2020003306A1 (es) | Composiciones bifuncionales para el tratamiento del cáncer. | |
| BR112022009563A2 (pt) | Compostos de pirrolotriazina atuando como inibidor de mnk |